Factors associated with the response of age-related macular degeneration to intravitreal ranibizumab treatment

American Journal of Ophthalmology

Volumn 154, Issue 1, 2012, Pages 125-136

  Yamashiro, Kenji ^a   Tomita, Kaoruko ^a   Tsujikawa, Akitaka ^a   Nakata, Isao ^a   Akagi Kurashige, Yumiko ^a   Miyake, Masahiro ^a   Ooto, Sotaro ^a   Tamura, Hiroshi ^a   Yoshimura, Nagahisa ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB;

AGED; ARTICLE; DISEASE ASSOCIATION; FEMALE; HUMAN; MALE; POLYPOIDAL CHOROIDAL VASCULOPATHY; PRIORITY JOURNAL; RETINA DETACHMENT; RETINA EDEMA; RETINA MACULA AGE RELATED DEGENERATION; RETINA NEOVASCULARIZATION; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; TREATMENT RESPONSE; VISUAL ACUITY;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CHOROID DISEASES; COLORING AGENTS; COMPLEMENT FACTOR H; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; INDOCYANINE GREEN; INTRAVITREAL INJECTIONS; MALE; PERIPHERAL VASCULAR DISEASES; POLYMORPHISM, SINGLE NUCLEOTIDE; POLYPS; PROTEINS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84862760298     PISSN: 00029394     EISSN: 18791891     Source Type: Journal    
DOI: 10.1016/j.ajo.2012.01.010     Document Type: Article

References (42)

1. Cho M, Barbazetto IA, Freund KB. Refractory neovascular age-related macular degeneration secondary to polypoidal choroidal vasculopathy. Am J Ophthalmol 2009;148(1):70-78.
2. Stangos AN, Gandhi JS, Nair-Sahni J, Heimann H, Pournaras CJ, Harding SP. Polypoidal choroidal vasculopathy masquerading as neovascular age-related macular degeneration refractory to ranibizumab. Am J Ophthalmol 2010;150(5):666-673.
3. Reche-Frutos J, Calvo-Gonzalez C, Donate-Lopez J, Garcia- Feijoo J, Leila M, Garcia-Sanchez J. Short-term anatomic effect of ranibizumab for polypoidal choroidal vasculopathy. Eur J Ophthalmol 2008;18(4):645-648.
4. Song JH, Byeon SH, Lee SC, Koh HJ, Kwon OW. Short-term safety and efficacy of a single intravitreal bevacizumab injection for the management of polypoidal choroidal vasculopathy. Ophthalmologica 2009;223(2):85-92.
5. Hikichi T, Ohtsuka H, Higuchi M, et al. Improvement of angiographic findings of polypoidal choroidal vasculopathy after intravitreal injection of ranibizumab monthly for 3 months. Am J Ophthalmol 2010;150(5):674-682.e671.
6. Cheng CK, Peng CH, Chang CK, Hu CC, Chen LJ. One-year outcomes of intravitreal bevacizumab (avastin) therapy for polypoidal choroidal vasculopathy. Retina 2011;31(5):846-856.
7. Lai T, Lee G, Luk F, Lam D. Intravitreal ranibizumab with or without photodynamic therapy for the treatment of symptomatic polypoidal choroidal vasculopathy. Retina 2011;31(8):1581-1588.
8. Saito M, Iida T, Kano M. Intravitreal ranibizumab for polypoidal choroidal vasculopathy with recurrent or residual exudation. Retina 2011;31(8):1589-1597.
9. Maruko I, Iida T, Saito M, Nagayama D, Saito K. Clinical characteristics of exudative age-related macular degeneration in Japanese patients. Am J Ophthalmol 2007;144(1):15-22.
10. Honda S, Imai H, Yamashiro K, et al. Comparative assessment of photodynamic therapy for typical age-related macular degeneration and polypoidal choroidal vasculopathy: a multicenter study in Hyogo prefecture, Japan. Ophthalmologica 2009;223(5):333-338.
11. Hayashi H, Yamashiro K, Gotoh N, et al. CFH and ARMS2 variations in age-related macular degeneration, polypoidal choroidal vasculopathy, and retinal angiomatous proliferation. Invest Ophthalmol Vis Sci 2010;51(11):5914-5919.
12. Nomura Y, Ueta T, Iriyama A, et al. Vitreomacular interface in typical exudative age-related macular degeneration and polypoidal choroidal vasculopathy. Ophthalmology 2011;118(5):853-859.
13. Koizumi H, Yamagishi T, Yamazaki T, Kawasaki R, Kinoshita S. Subfoveal choroidal thickness in typical agerelated macular degeneration and polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol 2011;249(8):1123-1128.
14. Bessho H, Honda S, Kondo N, Negi A. The association of age-related maculopathy susceptibility 2 polymorphisms with phenotype in typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. Mol Vis 2011;17:977-982.
15. Sakurada Y, Kubota T, Imasawa M, Mabuchi F, Tanabe N, Iijima H. Association of LOC387715 A69S genotype with visual prognosis after photodynamic therapy for polypoidal choroidal vasculopathy. Retina 2010;30(10):1616-1621.
16. Tsuchihashi T, Mori K, Horie-Inoue K, et al. Complement factor H and high-temperature requirement A-1 genotypes and treatment response of age-related macular degeneration. Ophthalmology 2011;118(1):93-100.
17. Boyer DS, Antoszyk AN, Awh CC, Bhisitkul RB, Shapiro H, Acharya NR. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007;114(2):246-252. (Pubitemid 46172497)
18. Kaiser PK, Brown DM, Zhang K, et al. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol 2007;144(6):850-857.
19. Takahashi M, Sato T, Kishi S. Intravitreal bevacizumab for age-related macular degeneration with good visual acuity. Jpn J Ophthalmol 2010;54(6):565-570.
20. Tano Y, Ohji M. EXTEND-I: safety and efficacy of ranibizumab in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Acta Ophthalmol 2010;88(3):309-316.
21. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355(14):1419-1431. (Pubitemid 44511557)
22. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355(14):1432- 1444. (Pubitemid 44511558)
23. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007;143(4): 566-583.
24. Uyama M, Wada M, Nagai Y, et al. Polypoidal choroidal vasculopathy: natural history. Am J Ophthalmol 2002;133(5): 639-648. (Pubitemid 34462012)
25. Ciardella AP, Donsoff IM, Huang SJ, Costa DL, Yannuzzi LA. Polypoidal choroidal vasculopathy. Surv Ophthalmol 2004;49(1):25-37. (Pubitemid 38056622)
26. Song MH, Ryu HW, Roh YJ. One-year results of intravitreal ranibizumab with or without photodynamic therapy for polypoidal choroidal vasculopathy. Ophthalmologica 2011; 226(3):119-126.
27. Kokame GT, Yeung L, Lai JC. Continuous anti-VEGF treatment with ranibizumab for polypoidal choroidal vasculopathy: 6-month results. Br J Ophthalmol 2011;94(3):297-301.
28. Gomi F, Sawa M, Sakaguchi H, et al. Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy. Br J Ophthalmol 2008;92(1):70-73.
29. Tsujikawa A, Ooto S, Yamashiro K, Tamura H, Otani A, Yoshimura N. Treatment of polypoidal choroidal vasculopathy by intravitreal injection of bevacizumab. Jpn J Ophthalmol 2011;54(4):310-319.
30. Otani A, Sasahara M, Yodoi Y, et al. Indocyanine green angiography: guided photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol 2007;144(1):7-14.
31. Brantley MA Jr, Fang AM, King JM, Tewari A, Kymes SM, Shiels A. Association of complement factor H and LOC387715 genotypes with response of exudative agerelated macular degeneration to intravitreal bevacizumab. Ophthalmology 2007;114(12):2168-2173. (Pubitemid 350181136)
32. Kloeckener-Gruissem B, Barthelmes D, Labs S, et al. Genetic association with response to intravitreal ranibizumab in patients with neovascular AMD. Invest Ophthalmol Vis Sci 2011;52(7):4694-4702.
33. Nischler C, Oberkofler H, Ortner C, et al. Complement factor H Y402H gene polymorphism and response to intravitreal bevacizumab in exudative age-related macular degeneration. Acta Ophthalmol 2011;89(4):e344-349.
34. McKibbin M, Ali M, Bansal S, et al. CFH, VEGF and HTRA1 promoter genotype may influence the response to intravitreal ranibizumab therapy for neovascular age-related macular degeneration. Br J Ophthalmol 2012;96(2):208-212.
35. Lee AY, Raya AK, Kymes SM, Shiels A, Brantley MA Jr. Pharmacogenetics of complement factor H (Y402H) and treatment of exudative age-related macular degeneration with ranibizumab. Br J Ophthalmol 2009;93(5):610-613.
36. Teper SJ, Nowinska A, Pilat J, Palucha A, Wylegala E. Involvement of genetic factors in the response to a variabledosing ranibizumab treatment regimen for age-related macular degeneration. Mol Vis 2010;16:2598-2604.
37. Imai D, Mori K, Horie-Inoue K, et al. CFH, VEGF, and PEDF genotypes and the response to intravitreous injection of bevacizumab for the treatment of age-related macular degeneration. J Ocul Biol Dis Infor 2010;3(2):53-59.
38. Kondo N, Bessho H, Honda S, Negi A. Complement factor H Y402H variant and risk of age-related macular degeneration in Asians: a systematic review and meta-analysis. Ophthalmology 2011;118(2):339-344.
39. Romano MR, Cipollone U, Semeraro F, Rinaldi M, Costagliola C. Combined photodynamic therapy and intravitreal bevacizumab for idiopathic polypoidal choroidal vasculopathy: one-year follow-up. Clin Ophthalmol 2010;4:1237-1241.
40. Tomita K, Tsujikawa A, Yamashiro K, et al. Treatment of polypoydal choroidal vasculopathy with photodynamic therapy combined with intravitreal injections of ranibizumab. Am J Ophthalmol 2012;153(1):68-80.
41. Yamaoka S, Okada AA, Sugahara M, Hida T. Clinical features of polypoidal choroidal vasculopathy and visual outcomes in the absence of classic choroidal neovascularization. Ophthalmologica 2010;224(3):147-152.
42. Zhang X, Wen F, Zuo C, Li M, Chen H, Wu K. Association of genetic variation on chromosome 9p21 with polypoidal choroidal vasculopathy and neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 2011;52(11):8063-8067.